Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 31 2014 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
FORM 12b-25
|
SEC FILE NUMBER
|
001-35737
CUSIP NUMBER
|
NOTIFICATION OF LATE FILING
|
66737P600
|
x
Form 10-K
¨
Form 20-F
¨
Form 11-K
¨
Form 10-Q
¨
Form 10-D
¨
Form N-SAR
¨
Form N-CSR
For Period Ended: December 31, 2013
¨
Transition Report on Form 10-K
¨
Transition Report on Form 20-F
¨
Transition Report on Form 11-K
¨
Transition Report on Form 10-Q
¨
Transition Report on Form N-SAR
For the Transition Period Ended:________________________
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify
the item(s) to which the notification relates:__________________________________
PART I - REGISTRANT INFORMATION
Northwest Biotherapeutics, Inc.
|
Full name of registrant
|
|
|
Former name if applicable:
|
|
4800 Montgomery Lane, Suite 800
|
Address of principal executive office
|
|
Bethesda, Maryland 20814
|
City, state and zip code
|
PART II - RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if
appropriate.)
(a) The reasons described in reasonable
detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
x
|
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form
N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date; and
|
(c) The accountant's statement or
other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.
The Company requires additional time to complete its year end
procedures. Those procedures could not be completed without incurring undue hardship and expense. The registrant undertakes
the responsibility to file such annual report no later than fifteen days after its original date.
PART IV - OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Linda
F. Powers
|
(240)
|
497-9024
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to
file such report(s) been filed? If the answer is no, identify report(s).
x
Yes
¨
No
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
¨
Yes
x
No
|
If so: attach an explanation of the anticipated change,
both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
Northwest Biotherapeutics, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 31, 2014
|
By:
|
/s/ Linda F. Powers
|
|
|
Name:
|
Linda F. Powers
|
|
Title:
|
President and Chief Executive Officer
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024